日本ケミファの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2025/01/21 | 1,479 | 1,483 | 1,474 | 1,483 | +2 | +0.1% | 4,400 |
| 2025/01/20 | 1,481 | 1,490 | 1,481 | 1,481 | -4 | -0.3% | 2,500 |
| 2025/01/17 | 1,493 | 1,513 | 1,485 | 1,485 | -10 | -0.7% | 2,800 |
| 2025/01/16 | 1,495 | 1,518 | 1,495 | 1,495 | -4 | -0.3% | 1,100 |
| 2025/01/15 | 1,501 | 1,501 | 1,499 | 1,499 | -5 | -0.3% | 1,100 |
| 2025/01/14 | 1,498 | 1,526 | 1,498 | 1,504 | +2 | +0.1% | 3,600 |
| 2025/01/10 | 1,508 | 1,508 | 1,502 | 1,502 | -6 | -0.4% | 800 |
| 2025/01/09 | 1,509 | 1,509 | 1,508 | 1,508 | -7 | -0.5% | 500 |
| 2025/01/08 | 1,506 | 1,515 | 1,506 | 1,515 | -7 | -0.5% | 500 |
| 2025/01/07 | 1,532 | 1,532 | 1,504 | 1,522 | +3 | +0.2% | 800 |
| 2025/01/06 | 1,520 | 1,538 | 1,503 | 1,519 | -1 | -0.1% | 1,000 |
| 2024/12/30 | 1,520 | 1,524 | 1,520 | 1,520 | +5 | +0.3% | 1,200 |
| 2024/12/27 | 1,506 | 1,519 | 1,500 | 1,515 | +15 | +1% | 2,400 |
| 2024/12/26 | 1,500 | 1,505 | 1,500 | 1,500 | ±0 | ±0% | 4,300 |
| 2024/12/25 | 1,492 | 1,500 | 1,492 | 1,500 | +4 | +0.3% | 3,000 |
| 2024/12/24 | 1,503 | 1,503 | 1,491 | 1,496 | -7 | -0.5% | 4,100 |
| 2024/12/23 | 1,512 | 1,512 | 1,500 | 1,503 | -8 | -0.5% | 2,900 |
| 2024/12/20 | 1,512 | 1,514 | 1,511 | 1,511 | -4 | -0.3% | 800 |
| 2024/12/19 | 1,512 | 1,515 | 1,511 | 1,515 | +1 | +0.1% | 1,700 |
| 2024/12/18 | 1,512 | 1,514 | 1,511 | 1,514 | +3 | +0.2% | 2,200 |
| 2024/12/17 | 1,520 | 1,520 | 1,511 | 1,511 | -6 | -0.4% | 1,600 |
| 2024/12/16 | 1,512 | 1,517 | 1,512 | 1,517 | +2 | +0.1% | 3,100 |
| 2024/12/13 | 1,513 | 1,521 | 1,513 | 1,515 | -6 | -0.4% | 1,500 |
| 2024/12/12 | 1,530 | 1,532 | 1,520 | 1,521 | -11 | -0.7% | 2,000 |
| 2024/12/11 | 1,525 | 1,532 | 1,513 | 1,532 | +17 | +1.1% | 2,600 |
| 2024/12/10 | 1,527 | 1,527 | 1,515 | 1,515 | +3 | +0.2% | 1,300 |
| 2024/12/09 | 1,539 | 1,556 | 1,512 | 1,512 | -12 | -0.8% | 4,600 |
| 2024/12/06 | 1,520 | 1,524 | 1,510 | 1,524 | +4 | +0.3% | 3,100 |
| 2024/12/05 | 1,520 | 1,520 | 1,520 | 1,520 | -1 | -0.1% | 1,300 |
| 2024/12/04 | 1,521 | 1,535 | 1,521 | 1,521 | ±0 | ±0% | 1,800 |
| 2024/12/03 | 1,529 | 1,530 | 1,521 | 1,521 | -12 | -0.8% | 1,700 |
| 2024/12/02 | 1,518 | 1,534 | 1,518 | 1,533 | +15 | +1% | 3,100 |
| 2024/11/29 | 1,517 | 1,518 | 1,517 | 1,518 | +2 | +0.1% | 1,500 |
| 2024/11/28 | 1,510 | 1,516 | 1,510 | 1,516 | +8 | +0.5% | 2,500 |
| 2024/11/27 | 1,510 | 1,510 | 1,508 | 1,508 | ±0 | ±0% | 900 |
| 2024/11/26 | 1,511 | 1,517 | 1,508 | 1,508 | ±0 | ±0% | 2,100 |
| 2024/11/25 | 1,515 | 1,515 | 1,508 | 1,508 | -3 | -0.2% | 3,800 |
| 2024/11/22 | 1,508 | 1,513 | 1,508 | 1,511 | -3 | -0.2% | 1,700 |
| 2024/11/21 | 1,500 | 1,514 | 1,500 | 1,514 | +13 | +0.9% | 1,400 |
| 2024/11/20 | 1,509 | 1,509 | 1,500 | 1,501 | -8 | -0.5% | 500 |
| 2024/11/19 | 1,500 | 1,522 | 1,500 | 1,509 | +9 | +0.6% | 4,900 |
| 2024/11/18 | 1,485 | 1,507 | 1,485 | 1,500 | +15 | +1% | 2,500 |
| 2024/11/15 | 1,485 | 1,506 | 1,485 | 1,485 | ±0 | ±0% | 800 |
| 2024/11/14 | 1,494 | 1,494 | 1,485 | 1,485 | -15 | -1% | 2,900 |
| 2024/11/13 | 1,500 | 1,500 | 1,500 | 1,500 | +3 | +0.2% | 400 |
| 2024/11/12 | 1,490 | 1,497 | 1,490 | 1,497 | +6 | +0.4% | 600 |
| 2024/11/11 | 1,490 | 1,505 | 1,490 | 1,491 | +1 | +0.1% | 1,700 |
| 2024/11/08 | 1,491 | 1,492 | 1,490 | 1,490 | -10 | -0.7% | 10,300 |
| 2024/11/07 | 1,500 | 1,522 | 1,500 | 1,500 | ±0 | ±0% | 1,400 |
| 2024/11/06 | 1,508 | 1,508 | 1,500 | 1,500 | -4 | -0.3% | 900 |
51～
100
件表示中 / 3673件
類似銘柄と比較する
現在ご覧いただいている「日ケミファ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 日ケミファ | 146,700円 | +2.5% | - | 3.41% | 88.21倍 | 0.29倍 |
|
中堅後発薬メーカー。長期収載品の主力は痛風薬ウラリット。新薬開発、検査薬事業を中期強化 |
| ペルセウス | 43,300円 | +20.0% | - | 0.00% | - | 3.63倍 |
|
東大発バイオベンチャー。高機能抗体の取得に強み。抗体医薬品や抗体薬物複合体（ＡＤＣ）開発 |
| ノイルイミューン | 14,700円 | -28.6% | - | 0.00% | - | 1.35倍 |
|
独自技術用いたＣＡＲ－Ｔ細胞免疫療法で抗がん剤を複数開発中。中外製薬とライセンス契約 |
| ＮＰＴ | - | - | - | - | - | - |
|
- |
| モダリス | 7,800円 | - | - | 0.00% | - | 1.63倍 |
|
遺伝子治療薬の創薬ベンチャー、ＤＮＡ切断しないエピゲノム編集に強み。研究開発中心は米国 |
市場注目の銘柄
チャート関連のコラム
